XOMA Ltd (NASDAQ: XOMA) reported Q4 EPS of ($0.55), which may not compare with the analyst estimate of ($0.19). Revenue ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings Guidance

Credit Suisse Downgrades XOMA, Ltd. (XOMA) to NeutralMarch 5, 2014 7:56 AM XOMA (XOMA) Sinks Over 15% on Trade ResumptionMarch 4, 2014 5:29 PM XOMA (XOMA) to Resume Trading at 5:25PM ETMarch 4, 2014 5:04 PM XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial ResultsMarch 4, 2014 4:57 PM XOMA (XOMA) Will Not Pursue Gevokizumab Development for EOA IndicationMarch 4, 2014 4:39 PM XOMA Provides Update on Gevokizumab Proof-of-Concept ProgramMarch 4, 2014 4:37 PM